Abstract Library

#2908 Re-Cellularised Human Pancreas 3D Scaffolds as a Novel Model for Biomarker Discovery in Pancreatic Neuroendocrine Tumours (pNETs)

Introduction: The lack of preclinical models of pNETs has challenged identification of tissue specific biomarkers of disease. Culturing cancer cells in their native tissue enables the close study of cell-ECM interaction and tissue remodelling. The biological products of such interactions can form a basis for discovery of novel biomarkers of the disease, and were previously linked with a range of inflammatory and malignant conditions.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ney A

Authors: Ney A, Al-Akkad W, Frenguelli L, Acedo P, Mazza G,

Keywords: 3d models, pancreatic neuroendocrine tumors, Biomarkers,

#1567 Pancreatic Neuroendocrine Tumors: Experience from a Single Institute

Introduction: A dedicated multidisciplinary team is necessary in the management of pancreatic neuroendocrine tumor (pNET).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Caff A, Cordio S, Pellegriti G, Russo M, Trovato M,

Keywords: pancreatic, Ki-67,

#1550 Very Early Response to Sunitinib in VHL Patient with Pancreatic Neuroendocrine Tumor

Introduction: Pancreatic neuroendocrine tumors (pNET) arise in 8-17% of Von Hippel Lindau (VHL) patients and surgery plays a key role for resectable lesions. Alternative medical therapy, such as target therapy (TT), can be used when surgery is unfeasible

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Caff A

Authors: Caff A, Cittadini G, De Cian F, Sciallero S, Malandrino P,

Keywords: VHL therapy,

#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma

Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: WALTER T

Authors: Walter T, Chardon L, Caffin A, Chopin-Laly X, Cohen R,

Keywords: polypeptide pancreatic, chromogranin A, gastroenteropancreatic neuroendocrine carcinoma, carcinoid, islet cell carcinoma, surrogate marker,